• We have a fully funded Phase 3 clinical program in a global partnership for Pracinostat worth up to $464 million.

    Welcome to our Annual Review
  • Emerging data positions our second drug candidate, a highly differentiated PI3K delta inhibitor, toward a pivotal study in the coming year.

    Welcome to our Annual Review
  • Our newest asset, a selective CDK inhibitor with potent inhibition of CDK9, addresses resistance to potential blockbuster drug Venclexta.

    Welcome to our Annual Review
  • We are led by a world-class management team with proven experience in oncology drug development, from discovery to approval.

    Welcome to our Annual Review
Read More

Shareholder Letter

Shareholder Letter

We begin our new fiscal year with strong momentum, a growing pipeline of clinical-stage oncology drug candidates and a healthy cash balance.

Learn More

Our Pipeline

Our Pipeline

One of our core strengths at MEI is identifying promising, differentiated oncology drug candidates, applying our drug development expertise to optimize their potential and, ultimately, making a meaningful impact on the lives of cancer patients.

Learn More

Expertise

Expertise

We are powered by a seasoned management team with a proven track record in developing the world's leading oncology drugs.

Learn More

Finance

Finance

We finished fiscal year 2017 with more cash on hand than when we started, due in large part to the $20 million in near-term payments we received in connection with our license, development and commercialization agreement with Helsinn, plus another $5 million in a related equity transaction, combined with a tightly managed spend.

Learn More